In-house Products
SK bioscience develops vaccines with its innovative technology and produces them under a strict quality control system.
The first Korean-developed COVID-19 Vaccine
SKYCovione™
(SARS-CoV-2, Surface Antigen (Recombinant DNA))
The world’s first-developed quadrivalent cell culture-based influenza vaccine
SKYCellflu® Quadrivalent Prefilled Syringe
(Cell Culture-Based Influenza Vaccine)
The WHO PQ certification obtained varicella vaccine
SKYVaricella®
(Live Attenuated Vaccine)
